OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development
20 nov. 2024 07h00 HE
|
OXB
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and...
Interim Results for the Six Months Ended 30 June 2024
23 sept. 2024 08h42 HE
|
OXB
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
18 sept. 2024 07h00 HE
|
OXB
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
02 sept. 2024 07h00 HE
|
Oxford BioMedica plc
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and...
Oxford Biomedica to host a free webinar showcasing its AAV expertise
27 août 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy...
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
08 août 2024 07h00 HE
|
Oxford BioMedica plc
Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...
Oxford Biomedica announces CFO transition
17 juil. 2024 07h06 HE
|
Oxford BioMedica plc
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”,...
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
05 mars 2024 07h00 HE
|
Oxford BioMedica plc
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...
Oxford Biomedica completes acquisition of ABL Europe
29 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple...
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
23 janv. 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...